The earnings call reflects a predominantly positive sentiment with significant achievements in sales growth, regulatory advancements, and clinical trial results. The company's strategic expansion in global markets and operational improvements further bolster this positive outlook. However, challenges such as ongoing net losses and early-stage community oncology expansion temper the overall sentiment.

Company Guidance

During Legend Biotech's second quarter 2025 earnings call, significant achievements and future guidance were highlighted. The company reported CARVYKTI net trade sales of approximately $439 million, marking a 136% increase year-over-year, and treated over 7,500 patients, underscoring the strength of their CAR-T launch. They anticipate achieving operational breakeven for CARVYKTI by the end of 2025 and company-wide profitability in 2026, excluding unrealized foreign exchange gains or losses. Regulatory updates included the FDA's removal of risk evaluation and mitigation strategies for certain CAR-T therapies, enhancing patient access. The company also discussed positive data from ASCO on CARVYKTI's survival rates and safety improvements, with a focus on expanding its reach in community settings and increasing manufacturing capacity. Legend Biotech's robust pipeline and strategic partnerships, including those with Novartis, were emphasized as key drivers for future growth. With a strong cash position of approximately $1 billion, the company remains committed to investing in cell therapy innovations.

Record-Breaking CAR-T Sales

During the second quarter, CARVYKTI net trade sales were approximately $439 million, marking a 136% increase year-over-year. This surpasses the previous CAR-T industry record of $414 million in a single quarter.

Regulatory Advancements Improve Patient Experience

The FDA has removed risk evaluation and mitigation strategies (REMS) for CAR-T therapies, leading to updated CARVYKTI labels that improve patient experience by reducing monitoring requirements.

Positive Clinical Trial Results

Long-term survival data from CARTITUDE-1 shows 1/3 of patients remain progression-free for 5 years or more. New data from ASCO and EHA also highlighted promising results for other pipeline products like LB1908 and LB2102.

Operational and Financial Improvements

Operating loss reduced to $22 million during the second quarter from $41 million a year ago, driven by operational efficiency and disciplined expense management. The company's cash position stands strong at $1 billion.

Expansion in Global Markets

CARVYKTI has expanded into multiple global markets, showing 4x sales growth outside the U.S. compared to the previous year.

Legend Biotech (LEGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LEGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 24, 2025	2025 (Q3)	-0.04 / -	-0.34	―	―	―
Aug 11, 2025	2025 (Q2)	-0.11 / -0.34	-0.05	-580.00% (-0.29)
May 13, 2025	2025 (Q1)	-0.21 / -0.27	-0.16	-68.75% (-0.11)
Mar 11, 2025	2024 (Q4)	-0.25 / 0.07	-0.4	117.50% (+0.47)
Nov 12, 2024	2024 (Q3)	-0.33 / -0.34	-0.17	-100.00% (-0.17)
Aug 09, 2024	2024 (Q2)	-0.29 / -0.05	-0.57	91.23% (+0.52)
May 13, 2024	2024 (Q1)	-0.19 / -0.16	-0.34	52.94% (+0.18)
Mar 11, 2024	2023 (Q4)	-0.36 / -0.40	-0.32	-25.00% (-0.08)
Nov 20, 2023	2023 (Q3)	-0.31 / -0.17	-0.37	54.05% (+0.20)	―
Aug 15, 2023	2023 (Q2)	-0.36 / -0.57	-0.35	-62.86% (-0.22)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LEGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$37.00	$36.24	-2.05%
May 13, 2025	$32.38	$31.08	-4.01%
Mar 11, 2025	$34.03	$37.19	+9.29%
Nov 12, 2024	$40.04	$40.18	+0.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Legend Biotech Corporation (LEGN) report earnings?

Legend Biotech Corporation (LEGN) is schdueled to report earning on Nov 24, 2025, After Close (Confirmed).

What is Legend Biotech Corporation (LEGN) earnings time?

Legend Biotech Corporation (LEGN) earnings time is at Nov 24, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LEGN EPS forecast?

LEGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing